- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07638657
Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder (alnico)
Investigating Autimia, a Digital Intervention for Patients With Autism Spectrum Disorder: Randomized Controlled Trial (Alnico Trial)
The goal of this clinical trial is to find out if autimia, a digital health intervention, can help adults with ASD (Autism Spectrum Disorder) manage their daily lives and improve their well-being.
The main questions it aims to answer are:
- Does autimia, together with regular treatment, improve health outcomes after three months better than regular treatment alone?
- Are the positive effects of autimia still noticeable after six months?
Researchers will compare two groups:
- Intervention group: Participants use the autimia intervention and continue their usual treatment.
- Control group: Participants continue with their usual treatment only.
Participants will:
- Participate in a video call with a specialist to confirm a diagnosis of ASD
- Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
- Continue with their usual treatment (both groups) and use autimia, a digital health intervention, for six months (intervention group only)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of autimia, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, autimia incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.
To ensure the inclusion of the appropriate target population, participants undergo a video-based diagnostic consultation with trained clinical professionals. This session involves a semi-structured interview and a standardized social behavior observation based on the ADOS-2 to confirm the diagnosis according to ICD-10-GM criteria.
Following confirmation, participants are randomly assigned to one of two groups. The intervention group receives immediate access to autimia for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.
Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the three-month follow-up. Data collected at the six-month mark will be utilized to assess the stability of the observed intervention effects.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Linda T. Betz, PhD
- Numéro de téléphone: +49 40 3510520
- E-mail: linda.betz@gaia-group.com
Sauvegarde des contacts de l'étude
- Nom: Anja Specht, MSc.
- Numéro de téléphone: +49 40 3510520
- E-mail: anja.specht@gaia-group.com
Lieux d'étude
-
-
-
Hamburg, Allemagne
- Recrutement
- GAIA AG
-
Contact:
- Anja Specht
- E-mail: anja.specht@gaia-group.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- prior suspected diagnosis of ASD by a healthcare professional
- diagnosis of ASD (ICD-10 codes: F84.5, F84.0, F84.1) confirmed in a semi-structured diagnostic interview conducted as a telemedical consultation
- IQ ≥ 80
- increased levels of psychological distress (DASS-21 total score ≥ 21)
- stable treatment (medication, psychotherapy, no treatment, …) for at least 30 days at the time of inclusion
- sufficient knowledge of the German language
- basic IT skills required for independent use of a digital intervention
- consent to participation
Exclusion Criteria:
- plans to change treatment (medication, psychotherapy, …) in the upcoming 3 months after inclusion
- diagnosis of another severe psychiatric disorder (acute severe affective disorder, acute psychotic disorder, acute substance use disorder, borderline personality disorder, antisocial personality disorder)
- acute suicidality
- currently being under legal guardianship for healthcare decisions
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Groupe de contrôle
Les participants affectés au groupe de contrôle auront accès au traitement comme d'habitude (TAU).
|
|
|
Expérimental: autimia
Participants will receive access to the digital health intervention autimia in addition to TAU.
|
Participants allocated to the intervention group will receive access to autimia in addition to treatment as usual (TAU). autimia is a digital health intervention designed for individuals with ASD (Autism Spectrum Disorder), accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by autimia are self-acceptance and self-worth, stress management and coping skills, optimizing the environment and communication, as well as understanding emotions and social interactions. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
21-item Depression, Anxiety, and Stress Scales (DASS-21) total score
Délai: 3 months
|
The DASS-21 is a 21-item PROM to assess psychological distress.
The total score is the sum of all items and ranges from 0 to 63.
Higher total scores indicate greater psychological distress and thus a worse outcome, whereas lower scores indicate fewer symptoms and a better outcome.
|
3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Work and Social Adjustment Scale (WSAS) total score
Délai: 3 months
|
The WSAS is a 5-item PROM to assess functional impairment in work, home life, and social activities.
The total score is the sum of all items and ranges from 0 to 40.
Higher total scores indicate greater disability and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.
|
3 months
|
|
Social Responsiveness Scale for Adults (SRS-A) total score
Délai: 3 months
|
The SRS-A is a 65-item PROM to assess social symptomatology in adults with ASD.
The total score is the sum of all items and ranges from 0 to 195.
Higher total scores indicate greater social impairment and thus a worse outcome, whereas lower scores indicate fewer symptoms and a better outcome.
|
3 months
|
|
Multidimensional Self Esteem Scale (MSWS) emotional self-esteem subscale score
Délai: 3 months
|
The MSWS is a PROM to assess self-esteem.
The emotional self-esteem subscale consists of 7 items to assess emotional self-worth.
The subscale score is the sum of these items and ranges from 7 to 49. Lower scores indicate lower self-esteem and thus a worse outcome, whereas higher scores indicate higher self-esteem and a better outcome.
|
3 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Isabel Dziobek, Prof. Dr., Humboldt-Universität zu Berlin
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- autimia RCT 2026
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .